

## AREV NANOTEC BRANDS INC.

## PRESS RELEASE

# **AREV Nanotec Joins BIOTECanada**

**VANCOUVER, BC / March 2, 2021 /** AREV NANOTEC BRANDS INC. (CSE: AREV) (OTC: AREVF) ("AREV Nanotec" or "AREV") is pleased to announce that the Company has become a member of BIOTECanada.

Since 1988, BIOTECanada, the national industry association representing Canada's biotechnology sector, has been the leading voice for the life science industry and works to advance the development of a globally competitive Canadian biotechnology ecosystem through constructive working relationships with policymakers and regulators. BIOTECanada also seeks to increase investment in Canadian biotechnology innovation, research, and commercialization with the aim of cultivating and promoting Canadian-based biotechnology companies in the global, competitive biotech market. (http://www.biotech.ca/).

Mike Withrow, CEO of AREV Nanotec, stated, "AREV Nanotec enthusiastically joins Canada's leading pharmaceutical companies and emerging biotech and biopharma companies by joining BIOTECanada. We strongly support BIOTECanada's effective advocacy and a robust regulatory voice in representing the collective interests of the Canadian biotechnology industry."

In 2003, BIOTECanada founded the national model for what has become Global Biotech Week (GBW). This year GBW2021 occurs worldwide from September 27 to October 3, 2021 to raise awareness of the industry and its global potential among policymakers, policy influencers and the general public more broadly. (<u>http://globalbiotechweek.ca</u>). BI-OTECanada also hosts annually its Gold Leaf Awards for company and individual excellence in contributing to the advancements in the Canadian biotechnology sector.

For further information, contact Mike Withrow, mike@AREVBrands.com 778-929-6536. For more information visit arevnanotec.com.

On behalf of the Board,

Mike Withrow CEO & Director

### About AREV NanoTec Brands Inc.

AREV NanoTec Brands Inc. (CSE: AREV) (OTC: AREVF) produces phytomedicinal extracts via its proprietary state-of-theart extraction methodologies for the life science industry. These premium ingredients are utilized in SUS-TAINN<sup>™</sup>, a Ready-To-Use Therapeutic Food (RUTF) to impact global malnutrition on Severe / Acute Malnutrition (SAM) and the Enteral Formula markets. The AREV model is to advance extraction technologies that provide opportunities for next generation phytomedicine. AREV Nanotec is a member of BIO, the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other countries.



## NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

#### FORWARD LOOKING INFORMATION

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forwardlooking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com.